Ann: Alterity Parkinson's and MSA Data Featured at AAN Meeting, page-15

Hi @Stockman,

Regarding the open label study, the fact that scientists are "experimenting" with dosages etc is the main reason I invested here.

The chances on more positive results increases significantly, plus the fact that patients are more suitable candidates due to them having had the disease for a short period, are all catalysts for success from ATH434.

And don't forget, they learnt from past trials and seem to have the dynamics right in this case.

p.s Bahamas or anywhere else is a real possibility here, just around the corner now and we will know one way or the other.

gltah